Skip to main content
Premium Trial:

Request an Annual Quote

JAX to Create New Genomics, Computational Biology Center with $10M Gift

NEW YORK (GenomeWeb) – The Jackson Laboratory today announced a $10 million gift to create a new genomics and computational biology research center.

The Roux Family Center for Genomics and Computation Biology is being created with a $5 million gift from technology investor David Roux and his wife Barbara and a matching $5 million donation from Jackson Lab in order to facilitate research into genetically based diseases, treatments for the disorders, and ways to prevent them. The new center is being endowed with three new faculty chair positions. A permanent fund will also be created to recruit staff and drive research and discovery, Jackson Lab said.

In a statement, Jackson Lab President and CEO Edison Liu noted the Roux's gift comes amid a challenging time for research organizations seeking public funding. The donation also comes a few weeks after the opening of the 183,500-square-foot Jackson Laboratory of Genomic Medicine on the campus of the University of Connecticut Health Center.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.